Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of caregiver burden with rivastigmine transdermal patch versus oral anti-dementia drugs in Alzheimer's disease
ChiCTR1900026313Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: ZBI score. Started Sep 2019; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR1900026313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026313.